Blueprint Medicines' earnings beat and significant sales growth are likely to positively impact investor sentiment and the stock price in the short term. The substantial outperformance compared to analyst expectations and the impressive year-over-year sales growth highlight the company's strong financial health and operational success, which could lead to increased investor confidence and demand for BPMC shares.